⏳ Fetching live dividend data...
Home › Calculator › SLRN Dividend Calculator 2026
Acelyrin, Inc. · NASDAQ
Price: $2.27 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in SLRN → $5.55M in 10 years · $216,491.60/month
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open SLRN position with:
Real after-tax yield depends on where you live and how you hold SLRN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 88.11% | 85.31% | $8,811 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 74.89% | 72.09% | $7,489 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 70.49% | 67.69% | $7,049 / yr |
| 🇬🇧 UK ISA | 0% | 88.11% | 85.31% | $8,811 / yr |
| 🇬🇧 UK Taxable | 8.75% | 80.40% | 77.60% | $8,040 / yr |
| 🇨🇦 TFSA | 0% | 88.11% | 85.31% | $8,811 / yr |
| 🇨🇦 CA Taxable | 25% | 66.08% | 63.28% | $6,608 / yr |
| 🇦🇺 Super (pension) | 15% | 74.89% | 72.09% | $7,489 / yr |
| 🇦🇺 AU Taxable | 30% | 61.68% | 58.88% | $6,168 / yr |
| 🇩🇪 DE Taxable | 26.375% | 64.87% | 62.07% | $6,487 / yr |
| 🇫🇷 FR Taxable | 30% | 61.68% | 58.88% | $6,168 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
SLRN pays quarterly — 4 times per year. Next ex-div: TBD.
How SLRN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SLRN sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2025-05-21 | 9,334,735 | — | — | ||
| A-Award | 2025-05-21 | 89,526 | $0.00 | $1.00 | ||
| D-Return | 2025-05-21 | 190,114 | $7.68 | $1.46M | ||
| D-Return | 2025-05-21 | 770,833 | $0.00 | $8.00 | ||
| D-Return | 2025-05-21 | 1,195,856 | $4.13 | $4.94M | ||
| D-Return | 2025-05-21 | 85,226 | $18.00 | $1.53M | ||
| D-Return | 2025-05-21 | 362,719 | $5.88 | $2.13M | ||
| D-Return | 2025-05-21 | 92,158 | $4.46 | $411.0K | ||
| D-Return | 2025-05-21 | 183,434 | $4.04 | $741.5K | ||
| D-Return | 2025-05-21 | 23,243 | $18.00 | $418.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SLRN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →